

Edgar Filing: CYTOGEN CORP - Form 8-K

CYTOGEN CORP
Form 8-K
August 01, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 1, 2003

CYTOGEN CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	000-14879	222322400
----- (State or Other Jurisdiction of Incorporation)	----- (Commission File Number)	----- (I.R.S. Employer Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ		08540
----- (Address of Principal Executive Offices)		----- (Zip Code)

Registrant's telephone number, including area code: (609) 750-8200

ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.

On August 1, 2003, Cytogen Corporation (the "Company") announced that the Company completed the reacquisition of marketing rights held by Berlex Laboratories, a U.S. affiliate of Schering AG, Germany, to QUADRAMET(R) (Samarium Sm 153 Lexidronam) in North and Latin America, in exchange for an upfront payment of \$8 million and royalties based on future sales. QUADRAMET is a skeletal targeting therapeutic radiopharmaceutical for the relief of pain due to bone metastases arising from prostate, breast, multiple myeloma and other types of cancer.

Such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing description of such press release is qualified in its entirety by reference to such document.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

Edgar Filing: CYTOGEN CORP - Form 8-K

(c) Exhibits.

Exhibit No. -----	Description -----
99.1	Press release of the Company dated August 1, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this current report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

CYTOGEN CORPORATION

By: /s/ Michael D. Becker

Michael D. Becker
President and Chief Executive
Officer

Dated: August 1, 2003

EXHIBIT INDEX

Exhibit No. -----	Description -----
99.1	Press release of the Company dated August 1, 2003.